Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration

Published:2021-10 Issue: Volume:Volume 15 Page:4317-4326
ISSN:1177-5483
Container-title:Clinical Ophthalmology
language:en
Short-container-title:OPTH

Author:

Sobolewska Bianka^ORCID,Sabsabi Muhammed,Ziemssen Focke^ORCID

Publisher

Informa UK Limited

Subject

Ophthalmology

Reference52 articles.

1. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

2. Ranibizumab for Neovascular Age-Related Macular Degeneration

3. The burden of neovascular age-related macular degeneration: a patient’s perspective

4. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration;Ophthalmology Science;2024-09

2. The impact of financial affordability on patient adherence to the dosing schedule of Anti-Vascular Endothelial Growth Factor in managing Diabetic Macular Edema.;2024-08-23

3. Switching from a Fixed Monthly Aflibercept Regimen to Bi-Monthly Brolucizumab in Refractory Cases of Neovascular Age-Related Macular Degeneration;Journal of Clinical Medicine;2024-06-12

4. Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects;PLOS ONE;2024-06-04

5. A TRP to Pathological Angiogenesis and Vascular Normalization;Comprehensive Physiology;2024-03-29